drugset / Trial / NCT06251076

Plan Development for Giving Teclistamab in the Outpatient Setting

NCT06251076

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a pilot study to develop an outpatient-based process for the administration of teclistamab for for relapsed/refractory multiple myeloma patients and to evaluate the burden on caregivers of patients receiving outpatient administration of teclistamab.

Timeline

Start
2024-11-19
Primary completion
2026-06-15
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Teclistamab Monoclonal antibody
Subject Tocilizumab Monoclonal antibody